In addition, therapies targeting IL-21 may be beneficial in AAV, where elevated IL-2 levels are associated with increased ANCA production and disease activity [63]. This evidence concerns the gene IL21 and anti-neutrophil cytoplasmic antibody-associated vasculitis.